Henri Rochefort
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Henri Rochefort has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
M Garcia
8 shared publicationsC Escot
Unité Hormones et Cancer, INSERM U 148, Montpellier, France
3 shared publicationsP Pujol
Service de Biologie Cellulaire, Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, France
3 shared publications- Pascal Roger
Groupe d'étude des facteurs pronostiques immunohistochimiques dans le cancer du sein, Unicancer, 101, rue de Tolbiac, 75654 Paris cedex 13, France
3 shared publications T Maudelonde
3 shared publicationsAnnick Lucas
INSERM U.148 and Department of Cell Biology, CHU de Montpellier-Hôpital Lapeyronie, Montpellier, France
2 shared publications
Latest Publications
- 30 November 2004
- Published by Elsevier in Annales de Pathologie
- Vol. 24, 132
Intérêt du niveau d’expression du REbeta dans la prédiction de la résistance des cancers du sein au Tamoxifène
- 30 November 2004
- Published by Elsevier in Annales de Pathologie
- Vol. 24, 132
Intérêt du niveau d’expression du REbeta dans la prédiction de la résistance des cancers du sein au Tamoxifène
- 15 March 2001
- Vol. 61 (6) , 2537-41
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
To understand the significance of estrogen receptor beta (ERbeta) in mammary carcinogenesis, we evaluated the expression of ERbeta in preinvasive mammary tumors. The percentage of ERbeta-positive epithelial or tumoral cells was assayed by quantitative immunohistochemistry using an image analyzer in 130 lesions of varying histological risk from 118 patients [71 with benign breast disease (BBD) and 59 with carcinoma in situ (CIS)] and compared with 118 adjacent histologically normal glands. Five groups of lesions with an increasing risk of invasive cancer, from BBD without hyperplasia to high-grade CIS, were studied. Results were compared with ERalpha and Ki67 immunostaining. The percentage of ERbeta-positive cells was high (median, 85%) in "normal" mammary glands and in nonproliferative BBD and decreased significantly (P < 0.0001) in proliferative BBD without atypia and in CIS, contrasting with an inverse progression for the ERalpha level. In normal mammary glands, the ERbeta level did not vary according to the nature of the lesion at the periphery and was significantly higher (P < 0.007) than in adjacent preinvasive lesions, except in nonproliferative BBD. The ERbeta level decreased in proliferative BBD, anticipating the ERalpha increase, which was significant in BBD with atypia. In high-grade ductal carcinoma in situ, both ER levels were low. The ratio between ERbeta and ERalpha was high in normal glands, and decreased significantly in proliferative lesions. ERbeta staining was inversely correlated with Ki67 (r = -0.333; P < 0.001), more particularly in high-grade ductal carcinoma in situ (r = -0.57; P < 0.02). The marked and early decreased level of ERbeta protein associated with other criteria of cell proliferation suggests a protective effect of ERbeta against the mitogenic activity of estrogens in mammary premalignant lesions. Knowledge of the ERbeta and ERalpha content in each preinvasive lesion should help to rationalize antiestrogen preventive therapy adapted to each individual patient.
- 15 March 2001
- Vol. 61 (6) , 2537-41
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
To understand the significance of estrogen receptor beta (ERbeta) in mammary carcinogenesis, we evaluated the expression of ERbeta in preinvasive mammary tumors. The percentage of ERbeta-positive epithelial or tumoral cells was assayed by quantitative immunohistochemistry using an image analyzer in 130 lesions of varying histological risk from 118 patients [71 with benign breast disease (BBD) and 59 with carcinoma in situ (CIS)] and compared with 118 adjacent histologically normal glands. Five groups of lesions with an increasing risk of invasive cancer, from BBD without hyperplasia to high-grade CIS, were studied. Results were compared with ERalpha and Ki67 immunostaining. The percentage of ERbeta-positive cells was high (median, 85%) in "normal" mammary glands and in nonproliferative BBD and decreased significantly (P < 0.0001) in proliferative BBD without atypia and in CIS, contrasting with an inverse progression for the ERalpha level. In normal mammary glands, the ERbeta level did not vary according to the nature of the lesion at the periphery and was significantly higher (P < 0.007) than in adjacent preinvasive lesions, except in nonproliferative BBD. The ERbeta level decreased in proliferative BBD, anticipating the ERalpha increase, which was significant in BBD with atypia. In high-grade ductal carcinoma in situ, both ER levels were low. The ratio between ERbeta and ERalpha was high in normal glands, and decreased significantly in proliferative lesions. ERbeta staining was inversely correlated with Ki67 (r = -0.333; P < 0.001), more particularly in high-grade ductal carcinoma in situ (r = -0.57; P < 0.02). The marked and early decreased level of ERbeta protein associated with other criteria of cell proliferation suggests a protective effect of ERbeta against the mitogenic activity of estrogens in mammary premalignant lesions. Knowledge of the ERbeta and ERalpha content in each preinvasive lesion should help to rationalize antiestrogen preventive therapy adapted to each individual patient.
- 15 February 2000
- Published by Wiley in International Journal of Cancer
- Vol. 85 (4) , 466-473
Stable amino-acid sequence of the Mannose-6-phosphate/insulin-like growth-factor-II receptor in ovarian carcinomas with loss of heterozygosity and in breast-cancer cell lines
The mannose-6-phosphate/insulin-like growth factor 2 receptor (Man-6-P/IGFII receptor) is involved in lysosomal enzyme sorting, IGFII degradation and pro-TGFβ activation. Genetic alterations in hepatocarcinomas and a few breast cancers suggest that this receptor behaves as a tumor suppressor. Moreover, hypersecretion and Man-6-P-independent targeting of cathepsins in breast and ovarian carcinomas also suggest alterations in this receptor. We studied the Man-6-P/IGFII receptor gene in 8 ovarian carcinomas, and 4 breast- and ovarian-cancer cell lines. The results confirmed a frequent loss of heterozygosity (LOH) in the 6q27-qter region in 5 out of 8 ovarian carcinomas. We used 23 overlapping RT-PCR fragments to sequence the whole coding region of the Man-6-P/IGFII receptor. The 2491 amino-acid sequence of this receptor was perfectly conserved in 9 out of 10 of our samples, including MCF7 and MDA-MB231 cells and 5 ovarian carcinomas with LOH. This allowed us to rectify the 2 previously published sequences which differed in several bases, and to propose a consensus amino-acid sequence. The only amino-acid change (Thr → Ala) was in BG1 ovarian-cancer cells, and was due to an A-to-G substitution on one allele at nucleotide 2561. We found no bi-allelic alterations in the 9 ovarian carcinomas, but 3 silent nucleotide substitutions leading to a lower cordon usage in 2 ovarian carcinomas with LOH. No mutation of the Man-6-P/IGFII receptor coding sequence was found in breast-cancer cell lines to explain the cathepsin-D hypersecretion and Man-6-P-independent trafficking described. We propose that, in breast and ovarian cancers, the frequent loss of one allele, associated with over-expression of some of its ligands, might be sufficient to saturate the receptor protein, displace the ligands to other sites, and consequently facilitate tumor progression. Int. J. Cancer 85:466–473, 2000.
- 15 February 2000
- Published by Wiley in International Journal of Cancer
- Vol. 85 (4) , 466-473
Stable amino-acid sequence of the Mannose-6-phosphate/insulin-like growth-factor-II receptor in ovarian carcinomas with loss of heterozygosity and in breast-cancer cell lines
The mannose-6-phosphate/insulin-like growth factor 2 receptor (Man-6-P/IGFII receptor) is involved in lysosomal enzyme sorting, IGFII degradation and pro-TGFβ activation. Genetic alterations in hepatocarcinomas and a few breast cancers suggest that this receptor behaves as a tumor suppressor. Moreover, hypersecretion and Man-6-P-independent targeting of cathepsins in breast and ovarian carcinomas also suggest alterations in this receptor. We studied the Man-6-P/IGFII receptor gene in 8 ovarian carcinomas, and 4 breast- and ovarian-cancer cell lines. The results confirmed a frequent loss of heterozygosity (LOH) in the 6q27-qter region in 5 out of 8 ovarian carcinomas. We used 23 overlapping RT-PCR fragments to sequence the whole coding region of the Man-6-P/IGFII receptor. The 2491 amino-acid sequence of this receptor was perfectly conserved in 9 out of 10 of our samples, including MCF7 and MDA-MB231 cells and 5 ovarian carcinomas with LOH. This allowed us to rectify the 2 previously published sequences which differed in several bases, and to propose a consensus amino-acid sequence. The only amino-acid change (Thr → Ala) was in BG1 ovarian-cancer cells, and was due to an A-to-G substitution on one allele at nucleotide 2561. We found no bi-allelic alterations in the 9 ovarian carcinomas, but 3 silent nucleotide substitutions leading to a lower cordon usage in 2 ovarian carcinomas with LOH. No mutation of the Man-6-P/IGFII receptor coding sequence was found in breast-cancer cell lines to explain the cathepsin-D hypersecretion and Man-6-P-independent trafficking described. We propose that, in breast and ovarian cancers, the frequent loss of one allele, associated with over-expression of some of its ligands, might be sufficient to saturate the receptor protein, displace the ligands to other sites, and consequently facilitate tumor progression. Int. J. Cancer 85:466–473, 2000.
- 1 February 2000
- Published by Elsevier in Clinica Chimica Acta
- Vol. 291 (2) , 157-170
Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview
- 1 February 2000
- Published by Elsevier in Clinica Chimica Acta
- Vol. 291 (2) , 157-170
Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview
- Open Access
- 15 March 1999
- Published by Wiley in International Journal of Cancer
- Vol. 80 (6) , 896-902
High-affinity antibodies from hen's-egg yolks against human mannose-6-phosphate/insulin-like growth-factor-II receptor (M6P/IGFII-R): Characterization and potential use in clinical cancer studies
The mannose‐6‐phosphate/insulin‐like growth‐factor‐II receptor (M6P/IGFII‐R) involved in trafficking of newly synthesized lysosomal enzymes, degradation of IGFII and activation of TGFβ1, was suggested as being coded by a tumor‐suppressor gene. No specific antibodies are currently available for clinical studies. Since M6P/IGFII‐R is a highly conserved protein in mammals, we immunized chicken with human M6P/IGFII‐R. Up to 200 mg of specific IgY from weekly pooled egg yolk was extracted by the polyethylene glycol procedure. Chicken IgY antibodies specifically recognized the human and bovine 270‐kDa M6P/IGFII‐R but not the 46‐kDa M6P‐R, as documented by immunoprecipitation and immunobloting. Using biosensor analysis, IgY antibodies were shown to bind M6P/IGFII‐R with high affinity (KD = 7.5 × 10−9M). A solid‐phase competitive ELISA using bovine M6P/IGFII‐R coated on 96‐well microplates, allowed us to titrate the M6P/IGFII‐R in human sera at a sensitivity of 300 ng/ml. The M6P/IGFII‐R was stained by immunoperoxidase in breast‐ and ovarian‐cancer cell lines (T47D, MDA‐MB231, MCF7 and BG1) and in frozen breast‐cancer tissues, showing predominant localization in the trans‐Golgi network. Staining specificity was shown with irrelevant IgY and by extinction with antigen excess. Quantitative immunohistochemical analysis of frozen sections from 40 invasive breast carcinomas indicated varying levels (from 5 to 400 units) of the M6P/IGFII‐R protein which were not correlated with tumor size, histological grade and estrogen receptor or progesterone receptor. There was a trend (p = 0.08) between lymph‐node invasiveness and low receptor level. Moreover, the M6P/IGFII‐R level was significantly lower in cancer cells than in normal cells in 10 out of the 21 tumors in which the peritumoral normal glands could be quantified in parallel. These 2 last results agree with the hypothesis of a tumor‐suppressor gene for this receptor and suggest more basic and clinical studies to prove it. Int. J. Cancer 80:896–902, 1999.
- 15 March 1999
- Published by Wiley in International Journal of Cancer
- Vol. 80 (6) , 896-902
Open AccessHigh-affinity antibodies from hen's-egg yolks against human mannose-6-phosphate/insulin-like growth-factor-II receptor (M6P/IGFII-R): Characterization and potential use in clinical cancer studies
The mannose‐6‐phosphate/insulin‐like growth‐factor‐II receptor (M6P/IGFII‐R) involved in trafficking of newly synthesized lysosomal enzymes, degradation of IGFII and activation of TGFβ1, was suggested as being coded by a tumor‐suppressor gene. No specific antibodies are currently available for clinical studies. Since M6P/IGFII‐R is a highly conserved protein in mammals, we immunized chicken with human M6P/IGFII‐R. Up to 200 mg of specific IgY from weekly pooled egg yolk was extracted by the polyethylene glycol procedure. Chicken IgY antibodies specifically recognized the human and bovine 270‐kDa M6P/IGFII‐R but not the 46‐kDa M6P‐R, as documented by immunoprecipitation and immunobloting. Using biosensor analysis, IgY antibodies were shown to bind M6P/IGFII‐R with high affinity (KD = 7.5 × 10−9M). A solid‐phase competitive ELISA using bovine M6P/IGFII‐R coated on 96‐well microplates, allowed us to titrate the M6P/IGFII‐R in human sera at a sensitivity of 300 ng/ml. The M6P/IGFII‐R was stained by immunoperoxidase in breast‐ and ovarian‐cancer cell lines (T47D, MDA‐MB231, MCF7 and BG1) and in frozen breast‐cancer tissues, showing predominant localization in the trans‐Golgi network. Staining specificity was shown with irrelevant IgY and by extinction with antigen excess. Quantitative immunohistochemical analysis of frozen sections from 40 invasive breast carcinomas indicated varying levels (from 5 to 400 units) of the M6P/IGFII‐R protein which were not correlated with tumor size, histological grade and estrogen receptor or progesterone receptor. There was a trend (p = 0.08) between lymph‐node invasiveness and low receptor level. Moreover, the M6P/IGFII‐R level was significantly lower in cancer cells than in normal cells in 10 out of the 21 tumors in which the peritumoral normal glands could be quantified in parallel. These 2 last results agree with the hypothesis of a tumor‐suppressor gene for this receptor and suggest more basic and clinical studies to prove it. Int. J. Cancer 80:896–902, 1999.
- 1 December 1998
- Vol. 58 (23) , 5367-73
Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis.
Although estrogen receptor (ER)-alpha is expressed in both benign and malignant ovarian tumors, the role of ER in ovarian carcinogenesis of epithelial tumors is still unknown. In view of the recent characterization of ER-beta, a second form of ER that seems to be highly expressed in ovaries, we reexamined this issue by studying the relative expression of ER-alpha and -beta in human ovarian tumor progression. We developed a competitive PCR assay based on coamplification of the two ERs in target nucleotide sequences displaying a high homology (exons 3 and 4). Coamplification experiments with varying amounts of plasmids containing ER-alpha and -beta cDNAs showed that this assay was reliable for discriminating as little as a 2-fold difference in the initial ER-alpha:ER-beta cDNA ratio. The relative expression of ER-alpha compared with ER-beta mRNAs was studied in human ovarian cancer cell lines (n = 5) and in normal ovaries (n = 6), then in human benign and malignant tumor samples including ovarian cysts (n = 24), borderline tumors (n = 3), and cancers (n = 10). In normal ovaries, ER-beta mRNA was the predominant ER form, whereas in ovarian cancer cell lines ER-alpha mRNA was markedly increased as compared with ER-beta. In benign and borderline tumors, ER-beta mRNA was detected in 78% of tumors, whereas ER-alpha mRNA was detected in 29%. In ovarian carcinomas, both ER-alpha and -beta mRNAs were expressed in 80% of tumors. The ER-alpha:ER-beta mRNA ratio was >1 in only one cyst sample (4%). In contrast, the ER-alpha:ER-beta mRNA ratio was markedly increased in ovarian cancers because 60% showed an ER-alpha:ER-beta mRNA >1. In situ hybridization experiments showed overlapping tissular distribution of ER-beta and -alpha expression in cancers and cysts, with a main localization in the epithelium and only a low level of expression in stromal cells. In summary, we found an increase in the ER-alpha:ER-beta mRNA ratio in ovarian carcinomas as compared with normal ovaries and cysts. These data suggest that overexpression of ER-alpha relative to ER-beta mRNA may be a marker of ovarian carcinogenesis.
- 1 December 1998
- Vol. 58 (23) , 5367-73
Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis.
Although estrogen receptor (ER)-alpha is expressed in both benign and malignant ovarian tumors, the role of ER in ovarian carcinogenesis of epithelial tumors is still unknown. In view of the recent characterization of ER-beta, a second form of ER that seems to be highly expressed in ovaries, we reexamined this issue by studying the relative expression of ER-alpha and -beta in human ovarian tumor progression. We developed a competitive PCR assay based on coamplification of the two ERs in target nucleotide sequences displaying a high homology (exons 3 and 4). Coamplification experiments with varying amounts of plasmids containing ER-alpha and -beta cDNAs showed that this assay was reliable for discriminating as little as a 2-fold difference in the initial ER-alpha:ER-beta cDNA ratio. The relative expression of ER-alpha compared with ER-beta mRNAs was studied in human ovarian cancer cell lines (n = 5) and in normal ovaries (n = 6), then in human benign and malignant tumor samples including ovarian cysts (n = 24), borderline tumors (n = 3), and cancers (n = 10). In normal ovaries, ER-beta mRNA was the predominant ER form, whereas in ovarian cancer cell lines ER-alpha mRNA was markedly increased as compared with ER-beta. In benign and borderline tumors, ER-beta mRNA was detected in 78% of tumors, whereas ER-alpha mRNA was detected in 29%. In ovarian carcinomas, both ER-alpha and -beta mRNAs were expressed in 80% of tumors. The ER-alpha:ER-beta mRNA ratio was >1 in only one cyst sample (4%). In contrast, the ER-alpha:ER-beta mRNA ratio was markedly increased in ovarian cancers because 60% showed an ER-alpha:ER-beta mRNA >1. In situ hybridization experiments showed overlapping tissular distribution of ER-beta and -alpha expression in cancers and cysts, with a main localization in the epithelium and only a low level of expression in stromal cells. In summary, we found an increase in the ER-alpha:ER-beta mRNA ratio in ovarian carcinomas as compared with normal ovaries and cysts. These data suggest that overexpression of ER-alpha relative to ER-beta mRNA may be a marker of ovarian carcinogenesis.
- Open Access
- 1 November 1998
- Published by Elsevier in The American Journal of Pathology
- Vol. 153 (5) , 1579-1588
Increased Immunostaining of Fibulin-1, an Estrogen-Regulated Protein in the Stroma of Human Ovarian Epithelial Tumors
- 1 November 1998
- Published by Elsevier in The American Journal of Pathology
- Vol. 153 (5) , 1579-1588
Open AccessIncreased Immunostaining of Fibulin-1, an Estrogen-Regulated Protein in the Stroma of Human Ovarian Epithelial Tumors
- Open Access
- 9 February 1998
- Published by Wiley in International Journal of Cancer
- Vol. 75 (4) , 654-658
Estradiol and fibulin‐1 inhibit motility of human ovarian‐ and breast‐cancer cells induced by fibronectin
- 9 February 1998
- Published by Wiley in International Journal of Cancer
- Vol. 75 (4) , 654-658
Open AccessEstradiol and fibulin‐1 inhibit motility of human ovarian‐ and breast‐cancer cells induced by fibronectin
- 2 November 1995
- Vol. 11 (9) , 1899-905
Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines.
The p21WAF1/CIP1 protein was shown to be a critical downstream effector of p53 and a potent inhibitor of cyclin-dependent kinases. We investigated the effects of exogenous p21WAF1/CIP1 in two different human breast carcinoma (HBC) cell lines MCF-7 and T47D. p21WAF1/CIP1 transfected cells formed significantly reduced number of drug-resistant colonies than their mock-transfected counterparts. The majority of the p21WAF1/CIP1 transfected MCF-7 cells acquired 50-100-fold increase in their sizes and persisted as single giant cells for several days without cell division, while the remainder underwent nuclear division (multiple nuclei) but were unable to complete cytokinesis, and finally all succumbed to apoptosis. Only few p21WAF1/CIP1 transfected T47D cells displayed increase in their sizes while a number of them formed small sized drug-resistant colonies which diminished in size due to cell death. The cells in these shrinking colonies exhibited characteristic signs of apoptosis such as chromatin condensation and fragmented nuclei while their membrane integrity was preserved. Thus in HBC cell lines the growth suppression due to enforced overexpression of p21WAF1/CIP1 is associated with giant cell formation and apoptosis.
- 2 November 1995
- Vol. 11 (9) , 1899-905
Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines.
The p21WAF1/CIP1 protein was shown to be a critical downstream effector of p53 and a potent inhibitor of cyclin-dependent kinases. We investigated the effects of exogenous p21WAF1/CIP1 in two different human breast carcinoma (HBC) cell lines MCF-7 and T47D. p21WAF1/CIP1 transfected cells formed significantly reduced number of drug-resistant colonies than their mock-transfected counterparts. The majority of the p21WAF1/CIP1 transfected MCF-7 cells acquired 50-100-fold increase in their sizes and persisted as single giant cells for several days without cell division, while the remainder underwent nuclear division (multiple nuclei) but were unable to complete cytokinesis, and finally all succumbed to apoptosis. Only few p21WAF1/CIP1 transfected T47D cells displayed increase in their sizes while a number of them formed small sized drug-resistant colonies which diminished in size due to cell death. The cells in these shrinking colonies exhibited characteristic signs of apoptosis such as chromatin condensation and fragmented nuclei while their membrane integrity was preserved. Thus in HBC cell lines the growth suppression due to enforced overexpression of p21WAF1/CIP1 is associated with giant cell formation and apoptosis.
- 1 September 1995
- Vol. 6 (9) , 1045-52
Transfected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth inhibitors.
Cathepsin D, a lysosomal protease, is overexpressed in primary breast cancer and associated with increased risk of metastasis. We have shown previously by transfection in rat tumor cells that overexpression of cathepsin D increased both experimental metastasis in nude mice and in vitro proliferation under low-serum conditions. In this study, we used the transfected cell lines to investigate the mechanism by which cathepsin D prevents density-dependent arrest of cell proliferation. This effect was not associated with a general alteration of cell-substratum or cell-cell adhesiveness. As shown by coculture and conditioned media experiments, control cells reaching saturation density released inhibitory activity that was able to prevent the growth of control or cathepsin D transfectants and decreased the cloning efficiency of normal rat kidney fibroblasts in agar. By contrast, in media from two cathepsin D-transfected cell lines, this inhibitory activity was markedly reduced. Cathepsin D overexpression did not affect cell sensitivity to the inhibitor but modified the secretion of several proteins. The increase in cell density appeared to be due to intracellular maturation of cathepsin D since it was reversed by amine treatment that neutralizes the pH of acidic compartments within the cells. Moreover, the addition of secreted pro-cathepsin D was unable to increase the saturation density of control clones. Finally, the inhibitory factor was partially characterized as a heat-labile, secreted protein. We conclude that cathepsin D overexpression increases the growth of cancer cells to a higher density via an intracellular mechanism, leading to a decreased secretion of growth inhibitor(s).
- 1 September 1995
- Vol. 6 (9) , 1045-52
Transfected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth inhibitors.
Cathepsin D, a lysosomal protease, is overexpressed in primary breast cancer and associated with increased risk of metastasis. We have shown previously by transfection in rat tumor cells that overexpression of cathepsin D increased both experimental metastasis in nude mice and in vitro proliferation under low-serum conditions. In this study, we used the transfected cell lines to investigate the mechanism by which cathepsin D prevents density-dependent arrest of cell proliferation. This effect was not associated with a general alteration of cell-substratum or cell-cell adhesiveness. As shown by coculture and conditioned media experiments, control cells reaching saturation density released inhibitory activity that was able to prevent the growth of control or cathepsin D transfectants and decreased the cloning efficiency of normal rat kidney fibroblasts in agar. By contrast, in media from two cathepsin D-transfected cell lines, this inhibitory activity was markedly reduced. Cathepsin D overexpression did not affect cell sensitivity to the inhibitor but modified the secretion of several proteins. The increase in cell density appeared to be due to intracellular maturation of cathepsin D since it was reversed by amine treatment that neutralizes the pH of acidic compartments within the cells. Moreover, the addition of secreted pro-cathepsin D was unable to increase the saturation density of control clones. Finally, the inhibitory factor was partially characterized as a heat-labile, secreted protein. We conclude that cathepsin D overexpression increases the growth of cancer cells to a higher density via an intracellular mechanism, leading to a decreased secretion of growth inhibitor(s).